Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela M Crook

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
BMC Medicine|October 28, 2017
Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosisMichael E Murphy, Patrick P J Phillips, Carl M Mendel, et al.
The New England Journal of Medicine|March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisFrancesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Lancet (London, England)|September 21, 2010
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trialSheena McCormack, Gita Ramjee, Anatoli Kamali, et al.
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
The New England Journal of Medicine|February 22, 2023
Treatment Strategy for Rifampin-Susceptible TuberculosisNicholas I Paton, Christopher Cousins, Celina Suresh, et al.
The Lancet. Infectious Diseases|May 25, 2025
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trialNicholas I Paton, Christopher Cousins, Intan P Sari, et al.
JAMA|May 22, 2017
Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical TrialPatrick B Murphy, Sunita Rehal, Gill Arbane, et al.
Trials|April 21, 2018
Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trialChishala Chabala, Anna Turkova, Margaret J Thomason, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
BMC Medicine|October 28, 2017
Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosisMichael E Murphy, Patrick P J Phillips, Carl M Mendel, et al.
The New England Journal of Medicine|March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisFrancesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Lancet (London, England)|September 21, 2010
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trialSheena McCormack, Gita Ramjee, Anatoli Kamali, et al.
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
The New England Journal of Medicine|February 22, 2023
Treatment Strategy for Rifampin-Susceptible TuberculosisNicholas I Paton, Christopher Cousins, Celina Suresh, et al.
The Lancet. Infectious Diseases|May 25, 2025
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trialNicholas I Paton, Christopher Cousins, Intan P Sari, et al.
JAMA|May 22, 2017
Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical TrialPatrick B Murphy, Sunita Rehal, Gill Arbane, et al.
Trials|April 21, 2018
Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trialChishala Chabala, Anna Turkova, Margaret J Thomason, et al.
Pageof 5